U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Sunshine Mills, Inc. - 618141 - 12/21/2023
  1. Warning Letters

CLOSEOUT LETTER

Sunshine Mills, Inc. MARCS-CMS 618141 —

Product:
Animal & Veterinary
Recipient:
Recipient Name
Mr. Alan Bostick
Recipient Title
CEO
Sunshine Mills, Inc.

PO Box 676
Red Bay, AL 35582
United States

Issuing Office:
Human and Animal Food East V Compliance Branch (HAFE5-CB)

United States

Secondary Issuing Offices

United States

Dear Mr. Bostick:

The Food and Drug Administration has completed evaluation of your firm’s corrective actions in response to our Warning Letter #618141, dated March 7, 2022. Based on our evaluation, it appears that you have addressed the violations contained in the Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.


Sincerely,
/S/
Allison C. Hunter
Compliance Officer

Back to Top